Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
about
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responsesAPRIL modulates B and T cell immunityProgresses towards safe and efficient gene therapy vectorsDeletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-CImmunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletionsCritical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpoxPre-clinical efficacy and safety of experimental vaccines based on non-replicating vaccinia vectors against yellow feverModified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseasesCandidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Viral vector-based influenza vaccines.UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in miceIdentification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccinesRecombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo.Modified vaccinia virus Ankara exerts potent immune modulatory activities in a murine modelModified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesStrikingly poor CD8+ T-cell immunogenicity of vaccinia virus strain MVA in BALB/c mice.Oncolytic targeting of androgen-sensitive prostate tumor by the respiratory syncytial virus (RSV): consequences of deficient interferon-dependent antiviral defense.Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception.Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Comparative analysis of MVA-CD40L and MVA-TRICOM vectors for enhancing the immunogenicity of chronic lymphocytic leukemia (CLL) cells.Thy1+ NK [corrected] cells from vaccinia virus-primed mice confer protection against vaccinia virus challenge in the absence of adaptive lymphocytes.Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunityImproving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara.Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus AnkaraDeletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigensNew hope for an AIDS vaccine.Protection of IFNAR (-/-) mice against bluetongue virus serotype 8, by heterologous (DNA/rMVA) and homologous (rMVA/rMVA) vaccination, expressing outer-capsid protein VP2Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies.Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling PathwaysVaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system.Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.T-cell Epitopes Identified by BALB/c Mice Immunized with Vaccinia Expressing HIV-1 Gag lie within immunodominant Regions Recognized by HIV-infected Indian Patients.NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses.
P2860
Q21135240-FFBD9A9E-EB28-408C-A200-8709ED5CEBC1Q24552299-103080B5-7E48-422C-9B13-2FCE1215D86BQ26781432-6C68B301-13AE-45B3-8198-DB9E81006AEFQ27306437-0455616C-32A3-410A-9413-3D3DF4D9C134Q27320923-97F13022-2CA4-4B25-B804-2445DC80DBCFQ27346933-410F0B1D-6E45-41E6-BE56-4C6FAF24B95EQ28740522-9DFE7248-E90A-4C81-AED3-8E8BD015DF3BQ30209342-4484941C-D771-4EC1-BD98-EDE934732957Q30375979-460F574D-85FA-4571-B336-2339F461C06BQ30390938-667B1771-C59D-4997-905B-101FB7734334Q30414377-F879A71E-7E5F-4E67-8778-EEB3A042CDE1Q30938741-72A3C9A5-3179-441D-8E6E-C75D4F836D3CQ33210436-115F7FB3-E80C-42D0-81F7-B303B234135AQ33320536-B10FB745-04C8-4FBA-BCDA-F52593AC2C14Q33328336-79CF684F-80EA-426C-A2A0-AC991510CE86Q33632203-125E8466-38E3-4706-9388-D39C5CBAD01FQ33653229-1B13B8CE-C9F0-400C-BB9E-A0D1CEB56F2DQ33680521-C77B07EA-BC1C-4C49-BE9C-5297BFDAA22EQ33806399-7FDF0911-767A-4360-A894-79251CEC8CCDQ33833779-A5CDD2B0-EA01-4E71-852D-96150E42ACFAQ33916776-E8093826-E275-460C-B706-4A1D8625E7C0Q33938820-6EAB7FC5-66C7-40AA-8A6C-1F5BEFE299B7Q33987473-C1CFE07C-9D10-4A7C-9159-9B8B6F07D1A8Q34172564-84FC0965-1FBC-413C-A358-DEECD3E2D6FFQ34182371-6A9F4787-01AF-43C4-8D7E-BCAEC046BB9AQ34247289-598CA41F-E8B7-4932-BB25-ED72BF45A0B8Q34262138-62F0B5E1-3914-496E-8E57-D34AE3817625Q34335296-FFDCE21E-23E2-4B6A-B9FD-BD5CBDB3096CQ34343169-D201DE16-ED2E-4A91-BBFA-C5EF0E83697FQ34465228-B3053A90-AF98-4FF8-A445-6821E5776CBCQ34632063-447827AF-CE7D-4A89-B9CD-A66F896B67CBQ34673436-16C544BE-28FB-4AE7-8979-A74D557550B8Q34720414-4B8CFE94-70C1-43DB-A974-4E17A1227A71Q34796206-169D9A6D-C9E5-48C1-BF2A-8E7F86DE7584Q34983603-C7FDDD13-D75F-44C0-9870-3425E9870C1CQ34991112-DCE4BD0E-AC07-4928-9776-23CEAFBA64C3Q35013206-8A34D826-5724-4E5B-860A-A41CA4B140D5Q35024193-060F9629-3168-4379-A1B7-249FCB9436A7Q35183962-7D853563-8E82-47FB-912F-C4E5A05A5DFEQ35212666-03919B8F-EBAA-4807-87F7-1BDDBA2CD333
P2860
Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Biology of attenuated modified ...... n and advantages as a vaccine.
@en
Biology of attenuated modified ...... n and advantages as a vaccine.
@nl
type
label
Biology of attenuated modified ...... n and advantages as a vaccine.
@en
Biology of attenuated modified ...... n and advantages as a vaccine.
@nl
prefLabel
Biology of attenuated modified ...... n and advantages as a vaccine.
@en
Biology of attenuated modified ...... n and advantages as a vaccine.
@nl
P2093
P2860
P1433
P1476
Biology of attenuated modified ...... n and advantages as a vaccine.
@en
P2093
J C Ramírez
M M Gherardi
P2860
P304
P356
10.1128/JVI.74.2.923-933.2000
P407
P577
2000-01-01T00:00:00Z